[1] Camelier AA, Winter DH, Jardim JR, Barboza CEG, Cukier A, Miravitlles M. Deficiência de alfa-1 antitripsina: diagnóstico e tratamento. J Bras Pneumol 2008;34:514–27.
[2] Blanco I, Lara B, de Serres F. Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema. Orphanet J Rare Dis 2011;6:14.
[3] Wood AM, Stockley RA. Alpha One Antitrypsin Deficiency: From Gene to Treatment. Respiration 2007;74:481–92.
[4] Kolarich D, Turecek PL, Weber A, Mitterer A, Graninger M, Matthiessen P, et al. Biochemical, molecular characterization, and glycoproteomic analyses of alpha-1 proteinase inhibitor products used for replacement therapy. Transfusion 2006;46:1959–77.
[5] Karnaukhova E. Recent advances in the research and development of alpha-1 proteinase inhibitor for therapeutic use. Lung Dis. State Art Rev., InTech; 2012.
[6] de Serres F, Blanco I. Role of alpha-1 antitrypsin in human health and disease. J Intern Med 2014;276:311–35.
[7] Rudnick DA, Perlmutter DH. Alpha-1-antitrypsin deficiency: A new paradigm for hepatocellular carcinoma in genetic liver disease. Hepatology 2005;42:514–21.
[8] Mulgrew AT, Taggart CC, McElvaney NG. Alpha-1-Antitrypsin Deficiency: Current Concepts. Lung 2007;185:191–201.
[9] Kelly E, Greene CM, Carroll TP, McElvaney NG, O’Neill SJ. Alpha-1 antitrypsin deficiency. Respir Med 2010;104:763–72.
[10] Law RHP, Zhang Q, McGowan S, Buckle AM, Silverman GA, Wong W, et al. An overview of the serpin superfamily. Genome Biol 2006;7:216.
[11] Lomas DA, Parfrey H. α1-Antitrypsin deficiency • 4: Molecular pathophysiology. Thorax 2004;59:529–35.
[12] Ioachimescu O, Stoller J. A Review of Alpha-1 Antitrypsin Deficiency. COPD J Chronic Obstr Pulm Dis 2005;2:263–75.
[13] Knaupp AS, Bottomley SP. Serpin polymerization and its role in disease-The molecular basis of α 1 -antitrypsin deficiency. IUBMB Life 2009;61:1–5.
[14] Kaplan A, Cosentino L. α1-Antitrypsin deficiency: Forgotten etiology. Can Fam Physician 2010;56:19–24.
[15] DeMeo DL, Silverman EK. Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax 2004;59:259–64.
[16] Stockley RA, Turner AM. α-1-Antitrypsin deficiency: clinical variability, assessment, and treatment. Trends Mol Med 2014;20:105–15.
[17] Greulich T, Nell C, Herr C, Vogelmeier C, Kotke V, Wiedmann S, et al. Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015. Orphanet J Rare Dis 2016;11:75.
[18] Stoller JK, Brantly M. The Challenge of Detecting Alpha-1 Antitrypsin Deficiency. COPD J Chronic Obstr Pulm Dis 2013;10:26–34.
[19] Chapman KR, Chorostowska-Wynimko J, Koczulla AR, Ferrarotti I, McElvaney NG. Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications. Int J Chron Obstruct Pulmon Dis 2018;Volume 13:419–32.
[20] Lomas DA, LI-Evans D, Finch JT, Carrell RW. The mechanism of Z α1-antitrypsin accumulation in the liver. Nature 1992;357:605–7.
[21] Lomas DA, Evans DL, Stone SR, Chang WSW, Carrell RW. Effect of the Z mutation on the physical and inhibitory properties of .alpha.1-antitrypsin. Biochemistry 1993;32:500–8.
[22] Mast AE, Enghild JJ, Salvesen G. Conformation of the reactive site loop of .alpha.1-proteinase inhibitor probed by limited proteolysis. Biochemistry 1992;31:2720–8.
[23] Stockley RA. Alpha1-antitrypsin Review. Clin Chest Med 2014;35:39–50.
[24] Mak G, Hanania NA. New bronchodilators. Curr Opin Pharmacol 2012;12:238–45.
[25] Torres-Durán M, Lopez-Campos JL, Barrecheguren M, Miravitlles M, Martinez-Delgado B, Castillo S, et al. Alpha-1 antitrypsin deficiency: outstanding questions and future directions. Orphanet J Rare Dis 2018;13:114.
[26] Malerba M, Radaeli A, Ceriani L, Tantucci C, Grassi V. Airway hyperresponsiveness in a large group of subjects with alpha1-antitrypsin deficiency: a cross-sectional controlled study. J Intern Med 2003;253:351–8.
[27] Fitchett DH, McNicol MW, Riordan JF. Intravenous salbutamol in management of status asthmaticus. Br Med J 1975;1:53–5.
[28] Uzkeser H, Cadirci E, Halici Z, Odabasoglu F, Polat B, Nurcan Yuksel T, et al. Anti-Inflammatory and Antinociceptive Effects of Salbutamol on Acute and Chronic Models of Inflammation in Rats: Involvement of an Antioxidant Mechanism. Mediators Inflamm 2012;2012:1–10.
[29] Malfait A-M, Malik AS, Marinova-Mutafchieva L, Butler DM, Maini RN, Feldmann M. The β2-Adrenergic Agonist Salbutamol Is a Potent Suppressor of Established Collagen-Induced Arthritis: Mechanisms of Action. J Immunol 1999;162:6278–83.
[30] Balint B, Watz H, Amos C, Owen R, Higgins M, Kramer B, et al. Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone. Int J Chron Obstruct Pulmon Dis 2010;5:311–8.
[31] Anderson GP. Formoterol: Pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective β2-adrenoceptor agonist bronchodilator. Life Sci 1993;52:2145–60.
[32] Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680–5.
[33] Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–54.
[34] Stoscheck CM. [6] Quantitation of protein, 1990, p. 50–68.
[35] Jha S, Agarwal S, Sanyal I, Jain GK, Amla D V. Differential subcellular targeting of recombinant human α₁-proteinase inhibitor influences yield, biological activity and in planta stability of the protein in transgenic tomato plants. Plant Sci 2012;196:53–66.
[36] Khodabandehloo A, Chen DDY. Particle sizing methods for the detection of protein aggregates in biopharmaceuticals. Bioanalysis 2017;9:313–26.
[37] Lorber B. Analytical light scattering methods in molecular and structural biology: Experimental aspects and results 2018.
[38] Beliciu CM, Moraru CI. Effect of solvent and temperature on the size distribution of casein micelles measured by dynamic light scattering. J Dairy Sci 2009;92:1829–39.
[39] Dietz AA, Hodges LK, Rubinstein HM, Briney RR. Estimation of the antitrypsin activity of serum. Clin Chem 1967;13:242–54.
[40] Devlin GL, Chow MKM, Howlett GJ, Bottomley SP. Acid Denaturation of α1-Antitrypsin: Characterization of a Novel Mechanism of Serpin Polymerization. J Mol Biol 2002;324:859–70.
[41] James EL, Bottomley SP. The Mechanism of α1-Antitrypsin Polymerization Probed by Fluorescence Spectroscopy. Arch Biochem Biophys 1998;356:296–300.
[42] Carrell RW, Lomas DA, Sidhar S, Foreman R. α1-Antitrypsin Deficiency. Chest 1996;110:243S-247S.
[43] Lomas DA. New insights into the structural basis of 1,-antitrypsin deficiency. QJM 1996;89:807–12.
[44] Stein PE, Carrell RW. What do dysfunctional serpins tell us about molecular mobility and disease? Nat Struct Mol Biol 1995;2:96–113.
[45] Hopkins PCR, Stone SR. The Contribution of the Conserved Hinge Region Residues of .alpha.1-Antitrypsin to Its Reaction with Elastase. Biochemistry 1995;34:15872–9.
[46] Hopkins PCR, Carrell RW, Stone SR. Effects of mutations in the hinge region of serpins. Biochemistry 1993;32:7650–7.
[47] Hopkins PCR, Chang W-SW, Wardell MR, Stone SR. Inhibitory Mechanism of Serpins MOBILITY OF THE C-TERMINAL REGION OF THE REACTIVE-SITE LOOP. J Biol Chem 1997;272:3905–9.
[48] James EL, Whisstock JC, Gore MG, Bottomley SP. Probing the Unfolding Pathway of α 1 -Antitrypsin. J Biol Chem 1999;274:9482–8.
[49] Dafforn TR, Mahadeva R, Elliott PR, Sivasothy P, Lomas DA. A Kinetic Mechanism for the Polymerization of α 1 -Antitrypsin. J Biol Chem 1999;274:9548–55.